Buspirone showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
Buspirone showed no clear difference in completion of scheduled treatment compared with placebo (low certainty).
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants experiencing adverse effects compared with placebo (moderate certainty).
N‐acetylcysteine showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).
N‐acetylcysteine showed no clear difference in participants experiencing adverse effects compared with placebo (moderate certainty).
N‐acetylcysteine showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
N‐acetylcysteine showed no clear difference in completion of scheduled treatment compared with placebo (moderate certainty).
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in completion of scheduled treatment compared with placebo (low certainty).
Selective serotonin reuptake inhibitor antidepressant showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants experiencing adverse effects compared with placebo (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes participants withdrawn due to adverse effects compared with placebo (very low certainty).
It is very uncertain whether selective serotonin reuptake inhibitor antidepressant changes completion of scheduled treatment compared with placebo (very low certainty).
Mixed action antidepressant showed no clear difference in participants abstinent at end of treatment compared with placebo (low certainty).